Cargando…

Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells

A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in...

Descripción completa

Detalles Bibliográficos
Autores principales: Galassi, Rossana, Luciani, Lorenzo, Gambini, Valentina, Vincenzetti, Silvia, Lupidi, Giulio, Amici, Augusto, Marchini, Cristina, Wang, Junbiao, Pucciarelli, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821381/
https://www.ncbi.nlm.nih.gov/pubmed/33490036
http://dx.doi.org/10.3389/fchem.2020.602845
_version_ 1783639412495613952
author Galassi, Rossana
Luciani, Lorenzo
Gambini, Valentina
Vincenzetti, Silvia
Lupidi, Giulio
Amici, Augusto
Marchini, Cristina
Wang, Junbiao
Pucciarelli, Stefania
author_facet Galassi, Rossana
Luciani, Lorenzo
Gambini, Valentina
Vincenzetti, Silvia
Lupidi, Giulio
Amici, Augusto
Marchini, Cristina
Wang, Junbiao
Pucciarelli, Stefania
author_sort Galassi, Rossana
collection PubMed
description A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in the azoles and/or the phosphane moieties to tune their hydrophilicity. Among the six candidates, only the compounds having the P-Au-N environment and not displaying neither the hydroxyl nor carboxyl groups in the ligands were found active. The compounds were screened by MTT tests in SKBR3, A17, and MDA-MB231 cancer cells, and two compounds (namely the 4,5-dicyano-imidazolate-1yl-gold(I)-(triphenylphosphane, 5, and 4,5-dichloro-imidazolate-1yl-gold(I)-triphenylphosphane, 6) were found very cytotoxic, with the most active with an IC(50) value of 3.46 μM in MDA-MB231 cells. By performing enzymatic assays in the treated cells lysates, the residual enzymatic activity of dihydrofolate reductase (DHFR) has been measured after cell treatment for 4 or 12 h in comparison with control cells. Upon 12 h of treatment, the activity of DHFR was significantly reduced in both SKBR3 and A17 cells by compounds 5 and 6, but not in human MDA-MB231 cells; interestingly, it was found remarkably high after 4 h of treatment, revealing a time dependence for the DHFR enzymatic assays. The DHFR inhibition data have been compared to those for the thioredoxin reductase (TrxR), the most recognized molecular target for gold compounds. For this latter, similar residual activities (i.e., 37 and 49% for the match of SKBR3 cells and compound 5 or 6, respectively) were found. Binding studies on the regards of ct-DNA (calf-thymus-DNA) and of plasma transporters proteins, such as BSA (bovine serum albumin) and ATF (apo transferrin), were performed. As expected for gold compounds, the data support strong binding to proteins (K(sv) values range: 1.51 ÷ 2.46 × 10(4) M(−1)) and a weaker interaction with ct-DNA's minor groove (K(sv) values range: 1.55 ÷ 6.12 × 10(3) M(−1)).
format Online
Article
Text
id pubmed-7821381
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78213812021-01-23 Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells Galassi, Rossana Luciani, Lorenzo Gambini, Valentina Vincenzetti, Silvia Lupidi, Giulio Amici, Augusto Marchini, Cristina Wang, Junbiao Pucciarelli, Stefania Front Chem Chemistry A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in the azoles and/or the phosphane moieties to tune their hydrophilicity. Among the six candidates, only the compounds having the P-Au-N environment and not displaying neither the hydroxyl nor carboxyl groups in the ligands were found active. The compounds were screened by MTT tests in SKBR3, A17, and MDA-MB231 cancer cells, and two compounds (namely the 4,5-dicyano-imidazolate-1yl-gold(I)-(triphenylphosphane, 5, and 4,5-dichloro-imidazolate-1yl-gold(I)-triphenylphosphane, 6) were found very cytotoxic, with the most active with an IC(50) value of 3.46 μM in MDA-MB231 cells. By performing enzymatic assays in the treated cells lysates, the residual enzymatic activity of dihydrofolate reductase (DHFR) has been measured after cell treatment for 4 or 12 h in comparison with control cells. Upon 12 h of treatment, the activity of DHFR was significantly reduced in both SKBR3 and A17 cells by compounds 5 and 6, but not in human MDA-MB231 cells; interestingly, it was found remarkably high after 4 h of treatment, revealing a time dependence for the DHFR enzymatic assays. The DHFR inhibition data have been compared to those for the thioredoxin reductase (TrxR), the most recognized molecular target for gold compounds. For this latter, similar residual activities (i.e., 37 and 49% for the match of SKBR3 cells and compound 5 or 6, respectively) were found. Binding studies on the regards of ct-DNA (calf-thymus-DNA) and of plasma transporters proteins, such as BSA (bovine serum albumin) and ATF (apo transferrin), were performed. As expected for gold compounds, the data support strong binding to proteins (K(sv) values range: 1.51 ÷ 2.46 × 10(4) M(−1)) and a weaker interaction with ct-DNA's minor groove (K(sv) values range: 1.55 ÷ 6.12 × 10(3) M(−1)). Frontiers Media S.A. 2021-01-11 /pmc/articles/PMC7821381/ /pubmed/33490036 http://dx.doi.org/10.3389/fchem.2020.602845 Text en Copyright © 2021 Galassi, Luciani, Gambini, Vincenzetti, Lupidi, Amici, Marchini, Wang and Pucciarelli. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Galassi, Rossana
Luciani, Lorenzo
Gambini, Valentina
Vincenzetti, Silvia
Lupidi, Giulio
Amici, Augusto
Marchini, Cristina
Wang, Junbiao
Pucciarelli, Stefania
Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
title Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
title_full Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
title_fullStr Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
title_full_unstemmed Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
title_short Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
title_sort multi-targeted anticancer activity of imidazolate phosphane gold(i) compounds by inhibition of dhfr and trxr in breast cancer cells
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821381/
https://www.ncbi.nlm.nih.gov/pubmed/33490036
http://dx.doi.org/10.3389/fchem.2020.602845
work_keys_str_mv AT galassirossana multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT lucianilorenzo multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT gambinivalentina multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT vincenzettisilvia multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT lupidigiulio multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT amiciaugusto multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT marchinicristina multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT wangjunbiao multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells
AT pucciarellistefania multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells